Our top pick for
B2Gold Corp is a gold business based in the US. B2Gold shares (BTG) are listed on the NYSE MKT and all prices are listed in US Dollars.
|Latest market close||$4.25|
|52-week range||$3.30 - $6.83|
|50-day moving average||$3.67|
|200-day moving average||$4.31|
|Wall St. target price||$5.72|
|Dividend yield||$0.16 (4.01%)|
|Earnings per share (TTM)||$0.55|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||7.59%|
|1 month (2021-09-23)||22.83%|
|3 months (2021-07-23)||7.87%|
|6 months (2021-04-23)||-16.17%|
|1 year (2020-10-22)||-37.50%|
|2 years (2019-10-22)||33.23%|
|3 years (2018-10-22)||61.60%|
|5 years (2016-10-21)||52.88%|
Valuing B2Gold stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of B2Gold's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
B2Gold's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, B2Gold shares trade at around 7x recent earnings.
B2Gold's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.71. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into B2Gold's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
B2Gold's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a B2Gold's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.7 billion|
|Operating margin TTM||44.72%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||14.46%|
|Return on equity TTM||24.89%|
|Market capitalisation||$4.2 billion|
TTM: trailing 12 months
There are currently 17.7 million B2Gold shares held short by investors – that's known as B2Gold's "short interest". This figure is 19.2% down from 21.9 million last month.
There are a few different ways that this level of interest in shorting B2Gold shares can be evaluated.
B2Gold's "short interest ratio" (SIR) is the quantity of B2Gold shares currently shorted divided by the average quantity of B2Gold shares traded daily (recently around 7.5 million). B2Gold's SIR currently stands at 2.36. In other words for every 100,000 B2Gold shares traded daily on the market, roughly 2360 shares are currently held short.
However B2Gold's short interest can also be evaluated against the total number of B2Gold shares, or, against the total number of tradable B2Gold shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case B2Gold's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 B2Gold shares in existence, roughly 20 shares are currently held short) or 0.0171% of the tradable shares (for every 100,000 tradable B2Gold shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against B2Gold.
Find out more about how you can short B2Gold stock.
Dividend payout ratio: 37.21% of net profits
Recently B2Gold has paid out, on average, around 37.21% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.01% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), B2Gold shareholders could enjoy a 4.01% return on their shares, in the form of dividend payments. In B2Gold's case, that would currently equate to about $0.16 per share.
While B2Gold's payout ratio might seem fairly standard, it's worth remembering that B2Gold may be investing much of the rest of its net profits in future growth.
B2Gold's most recent dividend payout was on 28 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 20 September 2021 (the "ex-dividend date").
Over the last 12 months, B2Gold's shares have ranged in value from as little as $3.3 up to $6.8272. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while B2Gold's is 0.8712. This would suggest that B2Gold's shares are less volatile than average (for this exchange).
B2Gold Corp. operates as a gold producer with three operating mines in Mali, the Philippines, and Namibia. It operates the Fekola Mine in Mali, the Masbate Mine in the Philippines, and the Otjikoto Mine in Namibia. The company also has an 81% interest in the Kiaka Project in Burkina Faso. In addition, it has a portfolio of other evaluation and exploration assets in Mali, Burkina Faso, Namibia, Uzbekistan, and Finland. B2Gold Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.